Body fat distribution modulates insulin sensitivity in post-menopausal overweight and obese women: A MONET study

International Journal of Obesity

Volumn 32, Issue 11, 2008, Pages 1626-1632

  Tousignant, B ^a   Faraj, M ^a,b   Conus, F ^a   Garrel, D ^a,b   Brochu, M ^c,d   Rabasa Lhoret, R ^a,b   Coderre, L ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITY INSTITUTE OF GERIATRICS OF SHERBROOKE   (Canada)

^d UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

Abdominal fat; Hyperinsulinemic euglycemic clamp; Insulin resistance; Peripheral fat; Visceral adipose tissue

Indexed keywords

GLUCOSE; INSULIN;

ADIPOSE TISSUE; ADULT; AGED; ARTICLE; BODY COMPOSITION; BODY FAT; CARDIOVASCULAR DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; POSTMENOPAUSE; PRIORITY JOURNAL;

ABDOMINAL FAT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN RESISTANCE; MIDDLE AGED; OBESITY; OVERWEIGHT; POSTMENOPAUSE; RISK ASSESSMENT;

EID: 56549102820     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2008.163     Document Type: Article

References (44)

1. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006; 444: 881-887.
2. Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G. Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J Clin Invest 1997; 100: 1166-1173.
3. Karelis AD, Brochu M, Rabasa-Lhoret R, Garrel D, Poehlman ET. Clinical markers for the identification of metabolically healthy but obese individuals. Diabetes Obes Metab 2004; 6: 456-457.
4. Conus F, Rabasa-Lhoret R, Peronnet F. Characteristics of metabolically obese normal-weight (MONW) subjects. Appl Physiol Nutr Metab 2007; 32: 4-12.
5. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 1998; 47: 1643-1649.
6. Karelis AD, Faraj M, Bastard JP, St-Pierre DH, Brochu M, Prud'homme D et al. The metabolically healthy but obese individual presents a favorable inflammation profile. J Clin Endocrinol Metab 2005; 90: 4145-4150.
7. Chan JM, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care 1994; 17: 961-969.
8. Kissebah AH, Peiris AN. Biology of regional body fat distribution: relationship to non-insulin-dependent diabetes mellitus. Diabetes Metab Rev 1989; 5: 83-109.
9. Despres JP. Is visceral obesity the cause of the metabolic syndrome? Ann Med 2006; 38: 52-63.
10. Folsom AR, Stevens J, Schreiner PJ, McGovern PG. Body mass index, waist/hip ratio, and coronary heart disease incidence in African Americans and whites. Atherosclerosis Risk in Communities Study Investigators. Am J Epidemiol 1998; 148: 1187-1194.
11. Megnien JL, Denarie N, Cocaul M, Simon A, Levenson J. Predictive value of waist-to-hip ratio on cardiovascular risk events. Int J Obes Relat Metab Disord 1999; 23: 90-97.
12. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 2005; 366: 1640-1649.
13. Snijder MB, Visser M, Dekker JM, Goodpaster BH, Harris TB, Kritchevsky SB et al. Low subcutaneous thigh fat is a risk factor for unfavourable glucose and lipid levels, independently of high abdominal fat. The Health ABC Study. Diabetologia 2005; 48: 301-308.
14. Paradisi G, Smith L, Burtner C, Leaming R, Garvey WT, Hook G et al. Dual energy X-ray absorptiometry assessment of fat mass distribution and its association with the insulin resistance syndrome. Diabetes Care 1999; 22: 1310-1317.
15. Gan SK, Kriketos AD, Poynten AM, Furler SM, Thompson CH, Kraegen EW et al. Insulin action, regional fat, and myocyte lipid: altered relationships with increased adiposity. Obes Res 2003; 11: 1295-1305.
16. Lau DC, Douketis JD, Morrison KM, Hramiak IM, Sharma AM, Ur E, Obesity Canada Clinical Practice Guidelines Expert Panel. 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]. CMAJ 2007; 176: S1-S13.
17. Balkau B, Deanfield JE, Després JP, Bassand JP, Fox KA, Smith Jr SC et al. International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries. Circulation 2007; 116: 1942-1951.
18. Bastard JP, Vandernotte JM, Faraj M, Karelis AD, Messier L, Malita FM et al. Relationship between the hyperinsulinemic-euglycaemic clamp and a new simple index assessing insulin sensitivity in overweight and obese postmenopausal women. Diabetes Metab 2007; 33: 261-268.
19. Karelis AD, Tousignant B, Nantel J, Proteau-Labelle M, Malita FM, St-Pierre DH et al. Association of insulin sensitivity and muscle strength in overweight and obese sedentary postmenopausal women. Appl Physiol Nutr Metab 2007; 32: 297-301.
20. American Diabetes Association. Screening for Diabetes. Diabetes Care 2002; 25: 21S-24S.
21. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: E214-E223.
22. Smith Jr SC. Multiple risk factors for cardiovascular disease and diabetes mellitus. Am J Med 2007; 120(3 Suppl 1): S3-S11.
23. Sowers JR. Obesity as a cardiovascular risk factor. Am J Med 2003; 115 (Suppl 8A): 37S-41S.
24. McFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001; 86: 713-718.
25. Lissner L, Björkelund C, Heitmann BL, Seidell JC, Bengtsson C. Larger hip circumference independently predicts health and longevity in a Swedish female cohort. Obes Res 2001; 9: 644-646.
26. Tanko LB, Bagger YZ, Alexandersen P, Larsen PJ, Christiansen C. Central and peripheral fat mass have contrasting effect on the progression of aortic calcification in postmenopausal women. Eur Heart J 2003; 24: 1531-1537.
27. Snijder MB, Dekker JM, Visser M, Bouter LM, Stehouwer CD, Yudkin JS et al. Hoorn study. Trunk fat and leg fat have independent and opposite associations with fasting and postload glucose levels: the Hoorn study. Diabetes Care 2004; 27: 372-377.
28. Ferreira I, Snijder MB, Twisk JW, van Mechelen W, Kemper HC, Seidell JC et al. Central fat mass versus peripheral fat and lean mass: opposite (adverse versus favorable) associations with arterial stiffness? The Amsterdam Growth and Health Longitudinal Study. J Clin Endocrinol Metab 2004; 89: 2632-2639.
29. Van Pelt RE, Evans EM, Schechtman KB, Ehsani AA, Kohrt WM. Contributions of total and regional fat mass to risk for cardiovascular disease in older women. Am J Physiol Endocrinol Metab 2002; 282: E1023-E1028.
30. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 2000; 21: 697-738.
31. Abdul-Ghani MA, Matsuda M, Balas B, DeFronzo RA. Muscle and liver insulin resistance indexes derived from the oral glucose tolerance test. Diabetes Care 2007; 30: 89-94.
32. Mulligan K, Grunfeld C, Tai VW, Algren H, Pang M, Chernoff DN et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000; 23: 35-43.
33. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP et al. ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
34. Yang X, Smith U. Adipose tissue distribution and risk of metabolic disease: does thiazolidinedione-induced adipose tissue redistribution provide a clue to the answer? Diabetologia 2007; 50: 1127-1139.
35. Akazawa S, Sun F, Ito M, Kawasaki E, Eguchi K. Efficacy of troglitazone on body fat distribution in type 2 diabetes. Diabetes Care 2000; 23: 1067-1071.
36. Kawai T, Takei I, Oguma Y, Ohashi N, Tokui M, Oguchi S et al. Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes. Metabolism 1999; 48: 1102-1107.
37. Smith SR, De Jonge L, Volaufova J, Li Y, Xie H, Bray GA. Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. Metabolism 2005; 54: 24-32.
38. Paniagua J, Gallego de la Sacristana A, Romero I, Vidal-Puig A, Latre JM, Sanchez E et al. MUFA-rich diet prevents central body fat distribution and decreases postprandial adiponectin expression induced by a carbohydrate-rich diet in insulin-resistant subjects. Diabetes Care 2007; 30: 1717-1723.
39. Smith U. Regional differences in adipocyte metabolism and possible consequences in vivo. Int J Obes 1985; 9(Suppl 1): 145-148.
40. Rebuffe-Scrive M, Enk L, Crona N, Lönnroth P, Abrahamsson L, Smith U et al. Fat cell metabolism in different regions in women. Effect of menstrual cycle, pregnancy, and lactation. J Clin Invest 1985; 75: 1973-1976.
41. Prentki M, Nolan CJ. Islet {beta} cell failure in type 2 diabetes. J Clin Invest 2006; 116: 1802-1812.
42. Havel PJ. Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism. Diabetes 2004; 53 (Suppl 1): S143-S151.
43. Lihn AS, Bruun JM, He G, Pedersen SB, Jensen PF, Richelsen B. Lower expression of adiponectin mRNA in visceral adipose tissue in lean and obese subjects. Mol Cell Endocrinol 2004; 219: 9-15.
44. Kelley DE. Skeletal muscle triglycerides: an aspect of regional adiposity and insulin resistance. Ann NY Acad Sci 2002; 967: 135-145.